Biopsy report explained

Mitotic Index in Your Biopsy: — What the Number Actually Counts

Your biopsy report may list a mitotic index or mitotic count. This tells your oncologist how many cells in the tumour sample were caught in the act of dividing — one measurement of how fast the tumour was reproducing.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

Cells caught mid-division — The pathologist counts cells that are visibly splitting — not all cells in the sample, only those observed in the act of dividing.
One factor among several — Mitotic count feeds into your tumour grade alongside cell shape and tissue organisation — not a standalone verdict on its own.
The threshold varies by cancer type — What counts as low or high differs between tumour types. Your result is read against reference ranges for your specific cancer, not a universal number.
Not a survival score — A high count does not translate directly to a prognosis. Your oncologist reads it as one piece of a larger clinical picture.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

Your biopsy report's mitotic index counts the number of cells your pathologist caught in the act of dividing. It tells your oncologist how fast the tumour was reproducing at the time of the biopsy. It is one of several factors used to determine your tumour grade — not a number that stands alone as a prediction.

What is the pathologist actually counting?

A mitotic figure is a cell that has been caught in the process of dividing into two. Under a microscope, dividing cells look distinctly different from resting cells — their chromosomes are arranged in visible patterns that identify which stage of division the cell is in.

The pathologist counts how many of these dividing cells appear in a defined area of the tissue slide. That area is usually expressed as a number of high-power fields — standardised microscope views — or as a physical area in square millimetres.

The result appears on your report as a count. The number is meaningful only when read against the reference range established for your specific cancer type.

Why does this number appear on your biopsy report?

Tumour grade describes how different the cancer cells look from normal cells and how fast they appear to be growing. Mitotic count is one of the measurements that feeds into grade, alongside features such as cell shape and how organised the tissue looks.

A tumour with more cells dividing is considered to be reproducing faster. Your oncologist uses this as one piece of information alongside your stage, imaging, and other test results.

The thresholds for what is considered low or high are published by pathology bodies including the WHO, and vary by tumour type. Your pathologist compares your count against those specific criteria — not against a single number that applies to all cancers.

What do the words on your report actually mean?

Mitotic count: The number of dividing cells the pathologist found in a defined area of your tissue sample, reported as a raw count.
Mitotic index: A related measure that expresses how many cells in the sample were dividing, often as a count per unit area. The two terms are sometimes used interchangeably, though they are calculated slightly differently.
High-power field (HPF): One standardised area of the microscope slide, viewed at high magnification. Counting is done across a set number of these fields so the result is consistent and comparable between laboratories.
Mitotic figure: A single dividing cell, visible under the microscope because of the characteristic arrangement of its chromosomes during the division process.
Tumour grade: An overall description of the tumour compiled by the pathologist from several scored features, of which mitotic count is one. Grade is distinct from stage, which describes how far the cancer has spread.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What does your mitotic count tell your team — and what does it not?

Aspect	What mitotic count provides	What it does not determine alone
Measurement	How many cells in the sample were dividing at the time of the biopsy	The division rate across the entire tumour, or how it may have changed since
Grade contribution	One scored component of your overall tumour grade	The complete grade — other features such as cell appearance are also scored
Treatment planning	Part of the biological picture your oncologist considers	Which treatment you will receive — that depends on your full clinical profile
Comparison over time	A baseline for future samples if you have a repeat biopsy	How the tumour has changed since the original biopsy was taken

How does your pathologist arrive at the mitotic count?

Why do reports say 'per 10 HPF' or 'per 2 mm²'?

HPF stands for high-power field — one standardised circle of view through the microscope at high magnification. When a report gives a count per 10 HPF, the pathologist examined ten of these fields and recorded how many dividing cells appeared across them in total. Some modern reports now express the same measurement per square millimetre of tissue instead, because different microscope models capture different-sized areas in a single field. Area-based reporting makes counts directly comparable between laboratories. Both formats are ways of anchoring the count to a consistent, defined denominator — which is what makes the numerator meaningful.

Why are the thresholds different for different cancers?

Different tumour types divide at naturally different rates, and the clinical significance of a given count varies accordingly. A count that places a tumour in a high-grade category for one cancer type may be unremarkable for another. The WHO Classification of Tumours and specialist pathology societies publish grading criteria for each major tumour type, and your pathologist applies the criteria for your specific cancer. This is why a number that appears in two different reports cannot be compared directly without knowing which tumour type each refers to.

Could two pathologists arrive at a different count from the same slide?

Yes, to a degree. Identifying mitotic figures requires experience and judgement — some cells resemble dividing cells under the microscope without actually being them, and how the tissue is prepared can affect visibility. This is a recognised limitation of the method, and it is one reason why specialist centres often seek a second pathology opinion on complex or borderline cases. If you want to know whether your slide was reviewed by more than one pathologist, it is a reasonable question to raise with your oncologist.

How does mitotic count relate to Ki-67?

Ki-67 is a protein present in cells that are dividing or preparing to divide, detected by a staining test on the same tissue. Like mitotic count, it is a measure of how proliferative the tumour is. The two approaches often point in the same direction, but they capture different biological moments: mitotic count identifies cells physically mid-division, while Ki-67 picks up a broader window of active cell-cycle phases. Some cancer types are graded using one; some use both. Your pathology report will reflect whichever approach applies to your tumour type.

Did you know?

Because different microscope models capture different areas in a single field of view, pathology societies have moved towards expressing mitotic counts per square millimetre of tissue rather than per high-power field.

This standardisation means a count from one laboratory is directly comparable to a count from another — which matters when your care involves more than one hospital or a specialist second opinion.

Source: WHO Classification of Tumours, 5th edition

Explore 114 more Waiting For and Understanding Your Report topics

Grade, Differentiation & Mitotic Index

Cytology Reporting Systems

Gleason & Prostate Biopsy Reporting

Margins, LVI and PNI

Reading Your Histopathology Report

Staging on a Biopsy Report

Waiting for Results

All Waiting For and Understanding Your Report →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

Does a high mitotic count mean the cancer is more dangerous?

A high mitotic count means the tumour was reproducing faster in the sampled area at the time of the biopsy. It is one factor your oncologist considers alongside stage, how abnormal the cells look, biomarker results, and your general health. It is not a standalone measure of severity. Before drawing a conclusion from the number alone, ask your oncologist to explain what it means in the context of your specific diagnosis — the count is meaningful only when read as part of the complete picture.

My report says 'increased mitotic activity' — what does that mean?

'Increased mitotic activity' is a phrase the pathologist uses when the count is above the expected range for that tumour type. It does not automatically mean it falls into the highest grade category — where exactly it sits depends on the grading criteria for your specific cancer. Ask your oncologist to explain where your count places you within those criteria and what the grading conclusion was overall. The phrase describes a finding; the grade gives it clinical context.

What does HPF mean on my biopsy report?

HPF stands for high-power field — one standardised view through a microscope at high magnification. When a report gives a count per 10 HPF, it means the pathologist examined ten of these fields and recorded the total number of dividing cells found across them. Some reports now use square millimetres of tissue instead of field count. Both are ways of ensuring the result is anchored to a defined area so it can be compared across laboratories.

Will the mitotic count be checked again if I have surgery or another biopsy?

Possibly. When surgery removes a tumour sample larger than the original biopsy, the pathologist examines it fully, and the grade — including mitotic count — may be confirmed or revised on that larger specimen. A biopsy taken later, for instance to assess a recurrence, is usually assessed fresh because tumour characteristics can change over time. Your treating team will tell you what further pathology is planned and at what points.

My report also lists Ki-67. Is that the same thing as the mitotic index?

Both Ki-67 and mitotic count measure how proliferative the tumour is, but they do so differently. Mitotic count identifies cells that are physically mid-division under the microscope. Ki-67 detects a protein present in cells that are in any active phase of the cell cycle, which is a broader window than division alone. The two often point in the same direction. Some cancers are graded using mitotic count, some using Ki-67, some using both. Your report will reflect the approach that applies to your tumour type.

Should I be worried about the number on my report?

It is understandable to focus on a number when you are trying to make sense of a biopsy report. Mitotic count is real information your oncologist needs — but it is one component of several that together produce your tumour grade, and your grade is one piece of your clinical picture alongside stage, imaging, and other tests. The number does not translate directly into a prediction. Ask your oncologist to explain what your specific count means in the context of your diagnosis, and what treatment approach follows from the full assessment.

Full index